A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UC

NCT05291689 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
39
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)